Dosimetric comparison between volumetric modulated arc therapy planning techniques for prostate cancer in the presence of intrafractional organ deformation.

blurred dose distribution dose–volume histogram intrafractional organ deformation prostate cancer treatment planning volumetric modulated arc therapy

Journal

Journal of radiation research
ISSN: 1349-9157
Titre abrégé: J Radiat Res
Pays: England
ID NLM: 0376611

Informations de publication

Date de publication:
10 Mar 2021
Historique:
received: 14 06 2020
revised: 24 09 2020
accepted: 30 09 2020
pubmed: 21 12 2020
medline: 4 11 2021
entrez: 20 12 2020
Statut: ppublish

Résumé

The purpose of this study was to compare single-arc (SA) and double-arc (DA) treatment plans, which are planning techniques often used in prostate cancer volumetric modulated arc therapy (VMAT), in the presence of intrafractional deformation (ID) to determine which technique is superior in terms of target dose coverage and sparing of the organs at risk (OARs). SA and DA plans were created for 27 patients with localized prostate cancer. ID was introduced to the clinical target volume (CTV), rectum and bladder to obtain blurred dose distributions using an in-house software. ID was based on the motion probability function of each structure voxel and the intrafractional motion of the respective organs. From the resultant blurred dose distributions of SA and DA plans, various parameters, including the tumor control probability, normal tissue complication probability, homogeneity index, conformity index, modulation complexity score for VMAT, dose-volume indices and monitor units (MUs), were evaluated to compare the two techniques. Statistical analysis showed that most CTV and rectum parameters were significantly larger for SA plans than for DA plans (P < 0.05). Furthermore, SA plans had fewer MUs and were less complex (P < 0.05). The significant differences observed had no clinical significance, indicating that both plans are comparable in terms of target and OAR dosimetry when ID is considered. The use of SA plans is recommended for prostate cancer VMAT because they can be delivered in shorter treatment times than DA plans, and therefore benefit the patients.

Identifiants

pubmed: 33341880
pii: 6042225
doi: 10.1093/jrr/rraa123
pmc: PMC7948894
doi:

Types de publication

Comparative Study Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

309-318

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Radiation Research Society and Japanese Society for Radiation Oncology.

Références

Int J Radiat Oncol Biol Phys. 2012 Mar 1;82(3):e399-407
pubmed: 22284036
Med Phys. 2010 Feb;37(2):505-15
pubmed: 20229859
BMC Cancer. 2016 Jul 15;16:484
pubmed: 27422044
J Med Imaging Radiat Sci. 2009 Mar;40(1):9-14
pubmed: 31051791
Radiother Oncol. 2007 Nov;85(2):201-6
pubmed: 17904671
Med Dosim. 2012 Spring;37(1):87-91
pubmed: 21925863
Int J Radiat Oncol Biol Phys. 2005 Jun 1;62(2):406-17
pubmed: 15890582
Radiother Oncol. 2014 Sep;112(3):418-24
pubmed: 24996454
Phys Med Biol. 2008 Jul 7;53(13):3567-78
pubmed: 18560049
Radiother Oncol. 2009 Nov;93(2):259-65
pubmed: 19748146
Radiother Oncol. 2004 Oct;73(1):21-32
pubmed: 15465142
Radiat Environ Biophys. 2009 Nov;48(4):385-9
pubmed: 19641930
Radiother Oncol. 2009 Nov;93(2):226-33
pubmed: 19765846
J Appl Clin Med Phys. 2015 Mar 08;16(2):5013
pubmed: 26103174
J Appl Clin Med Phys. 2013 May 06;14(3):4053
pubmed: 23652240
Radiol Oncol. 2017 Jan 15;51(1):112-120
pubmed: 28265240
Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):224-35
pubmed: 11777642
Int J Radiat Oncol Biol Phys. 2010 Mar 1;76(3):935-42
pubmed: 20044214
Phys Med Biol. 2002 Jul 7;47(13):2203-20
pubmed: 12164582
Radiat Oncol. 2012 Apr 02;7:56
pubmed: 22472040
Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1403-14
pubmed: 1938548
Int J Radiat Oncol Biol Phys. 2008 Mar 15;70(4):1247-55
pubmed: 18313531
Int J Radiat Oncol Biol Phys. 2014 Apr 1;88(5):1167-74
pubmed: 24661670
Med Phys. 2007 Mar;34(3):923-34
pubmed: 17441238
Med Phys. 2008 Jan;35(1):310-7
pubmed: 18293586
Phys Imaging Radiat Oncol. 2019 Mar 06;9:69-76
pubmed: 33458428
Med Phys. 2013 Jul;40(7):071718
pubmed: 23822422
PLoS One. 2017 Mar 10;12(3):e0173643
pubmed: 28282417
J ICRU. 2010 Apr;10(1):27-40
pubmed: 24173325
Med Phys. 2005 Feb;32(2):396-404
pubmed: 15789585
Phys Med Biol. 2005 Jun 21;50(12):2779-98
pubmed: 15930602
Int J Radiat Oncol Biol Phys. 2006 Jun 1;65(2):528-34
pubmed: 16690435
Phys Med. 2007 Dec;23(3-4):115-25
pubmed: 17825595
Australas Radiol. 2005 Jun;49(3):222-9
pubmed: 15932465
Phys Med Biol. 2006 May 7;51(9):2237-52
pubmed: 16625039
Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22
pubmed: 2032882
Acta Oncol. 2013 Oct;52(7):1451-7
pubmed: 23968261
Ann ICRP. 2000;30(3):7-70
pubmed: 11711147
Int J Radiat Oncol Biol Phys. 2008 Jul 15;71(4):1084-90
pubmed: 18280057
Radiat Oncol. 2014 Aug 08;9:174
pubmed: 25106679
Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):664-71
pubmed: 19473781
Med Phys. 2003 Aug;30(8):2001-11
pubmed: 12945966
Int J Radiat Biol. 1992 Aug;62(2):249-62
pubmed: 1355519
Adv Radiat Oncol. 2017 Mar 28;2(3):429-436
pubmed: 29114612
Int J Radiat Oncol Biol Phys. 2006 Feb 1;64(2):625-34
pubmed: 16343802
Am J Clin Oncol. 2010 Feb;33(1):11-6
pubmed: 19730351
Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):568-75
pubmed: 12243837
J Med Imaging Radiat Oncol. 2011 Dec;55(6):611-21
pubmed: 22141609
Radiother Oncol. 2010 Jun;95(3):261-8
pubmed: 20363041
Int J Radiat Oncol Biol Phys. 2018 Feb 1;100(2):306-316
pubmed: 29229323
Radiother Oncol. 2019 Jan;130:82-88
pubmed: 30336955
Radiother Oncol. 2003 Jan;66(1):19-28
pubmed: 12559517
Int J Radiat Oncol Biol Phys. 2001 May 1;50(1):265-78
pubmed: 11316572
Int J Radiat Oncol Biol Phys. 2015 Jul 15;92(4):779-86
pubmed: 25936816
Radiother Oncol. 2010 May;95(2):191-7
pubmed: 20189667
Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):993-1002
pubmed: 15752878
J BUON. 2014 Jan-Mar;19(1):297-303
pubmed: 24659679
Br J Radiol. 2014 Oct;87(1042):20140343
pubmed: 25138155
J Radiat Res. 2011;52(2):199-207
pubmed: 21436610

Auteurs

Maria Varnava (M)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamadaoka, Suita, Osaka, 565-0871, Japan.

Iori Sumida (I)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamadaoka, Suita, Osaka, 565-0871, Japan.

Michio Oda (M)

Department of Medical Technology, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Keita Kurosu (K)

Department of Medical Technology, Osaka University Hospital, 2-15 Yamadaoka, Suita, Osaka, 565-0871, Japan.

Fumiaki Isohashi (F)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamadaoka, Suita, Osaka, 565-0871, Japan.

Yuji Seo (Y)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamadaoka, Suita, Osaka, 565-0871, Japan.

Keisuke Otani (K)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamadaoka, Suita, Osaka, 565-0871, Japan.

Kazuhiko Ogawa (K)

Department of Radiation Oncology, Osaka University Graduate School of Medicine, 2-2 (D10) Yamadaoka, Suita, Osaka, 565-0871, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH